Hemo.Labs

Hemo.Labs is a reliable SaaS platform that provides early disease diagnosis, improving the accuracy, speed, and accessibility of medical services. We address issues such as delayed diagnoses, a shortage of specialists, and diagnostic errors through an innovative approach to disease prevention and early detection.

Currently, people spend large amounts of money on treating advanced diseases, wasting time in queues and visiting doctors. We offer a convenient way to regularly undergo check-ups (1-2 times a year) with specialists visiting homes and automated diagnostics with recommendations.

Users save time and money by receiving accurate diagnoses and recommendations without the need to visit clinics. Instead of treating advanced diseases, we help prevent their development, making healthcare accessible, convenient, and effective.

Our Hemo.Labs platform uses:

Artificial intelligence and big data to predict the risks of multiple chronic diseases (MLTC) and prevent them.
Global preventive protocols to timely identify predispositions to diseases.
RAG technology (Retrieval-Augmented Generation) for generating accurate recommendations without errors or "hallucinations."
Integrated solutions (Hemo Fusion) that provide reliable results and assist doctors in obtaining a second opinion.

Working solution

1. SMB (Small and Medium Business) - contributes to improving employee health, increasing staff loyalty, and enhancing business efficiency by boosting productivity and immunity.

2. Healthcare and Medicine -

Preventive medicine (early disease diagnosis) helps reduce the burden on healthcare systems.
Optimization of clinic and hospital operations through automated diagnostic systems.

Hemo.Labs demonstrates its impact on both business and society through early diagnostics and the implementation of preventive measures. In the case of Company A, it was discovered that 12 out of 13 employees had health issues, including autoimmune diseases and metabolic disorders such as insulin resistance and prediabetes. Timely recommendations allowed for preventive treatment, preventing the development of complications and severe stages of the diseases. This led to increased productivity and energy levels among employees, as well as improved employee loyalty.

The implementation of regular screening programs helps detect hidden diseases at early stages and enhances employee satisfaction. At the societal level, the project improves quality of life by promoting prevention and a healthy lifestyle, which also reduces the burden on the healthcare system.

The technologies used by Hemo.Labs, based on artificial intelligence and big data processing, increase the accuracy and accessibility of diagnostics, fostering trust in digital healthcare solutions. As a result, businesses gain healthy and motivated employees, and society adopts a more conscious approach to disease prevention.

3000+ free diagnostics
50+ checkups (2 companies), 10+ detected autoimmune processes
20+ recommendations on diets and vitamins for preventing complications.
MRR 1000+$

Hemo.Labs stands out in the market for its diagnostic accuracy (99%) and user convenience. We utilize AI+RAG for reliable, hallucination-free recommendations and process large datasets to predict MLTC (72%), minimizing the development of other chronic conditions if one is already present. Check-up orders are handled via a Telegram bot, and services are provided at home, saving employees time and money. Integration of global prevention protocols and personalized recommendations enables early disease detection and reduces the risk of their progression.

Hemo.Labs project has high scaling potential ($24 billion). The current diagnostic and disease prevention market in our country is small, which limits internal growth opportunities. However, we aim to expand our presence in international markets, including the MENA region and Indonesia, where there is high demand for affordable and effective healthcare solutions.

Particularly promising areas of development include integration with local healthcare systems, the implementation of telemedicine technologies, and personalized recommendations based on regional health characteristics. Improving our platform to account for cultural and medical specifics of new markets will allow us to reach a global level and make a significant contribution to preventive medicine.

White Hill Capital – won the competition for the best idea and are discussing further conditions for entering the Saudi Arabia market.
Nuris NU – won the Potential Unicorn Award and a $3,000 prize.